Frequency of EGFR and KRAS mutations in lung adenocarcinomas in african americans

Journal of Thoracic Oncology

Volumn 6, Issue 1, 2011, Pages 28-31

  Reinersman, J Matthew ^a   Johnson, Melissa L ^a   Riely, Gregory J ^a   Chitale, Dhananjay A ^a   Nicastri, Anthony D ^b   Soff, Gerald A ^c   Schwartz, Ann G ^d   Sima, Camelia S ^a   Ayalew, Getinet ^b   Lau, Christopher ^a   Zakowski, Maureen F ^a   Rusch, Valerie W ^a   Ladanyi, Marc ^a   Kris, Mark G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SUNY Downstate Medical Center   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

African Americans; EGFR mutation; KRAS; Racial differences

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; PRIORITY JOURNAL;

EID: 78651087933     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181fb4fe2     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
3. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500.
4. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311.
5. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
6. Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 2006;24:2158-2163.
7. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
8. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909.
9. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007;13:2890-2896.
10. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731-5734.
11. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:839-844.
12. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005;7:396-403.
13. Li AR, Chitale D, Riely GJ, et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 2008;10: 242-248.
14. Hunt JD, Strimas A, Martin JE, et al. Differences in KRAS mutation spectrum in lung cancer cases between African Americans and Caucasians after occupational or environmental exposures to known carcinogens. Cancer Epidemiol Biomarkers Prev 2002;11:1405-1412.
15. Rodenhuis S. RAS oncogenes and human lung cancer. In HI Pass, JB Mitchell, DH Johnson, et al. (Eds.), Lung Cancer Principles and Practice. Philadelphia, PA: Lippincott-Raven Publishers, 1996. Pp. 73-82.
16. Yang SH, Mechanic LE, Yang P, et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2005;11:2106-2110.
17. Tsao AS, Tang XM, Sabloff B, et al. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol 2006;1:231-239.
18. Leidner RS, Fu P, Clifford B, et al. Genetic abnormalities of the EGFR pathway in African American patients with non-small cell lung cancer. J Clin Oncol 2009;27:5620-5626.
19. Krishnaswamy S, Kanteti R, Duke-Cohan JS, et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 2009;15:5714-5723.